Health

Oculis to Participate in Upcoming Investor Conferences

ZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a…

4 weeks ago

Oculis Publishes 2025 Consolidated Financial Statements

ZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Following the Company‘s press release published on March 3, the audited consolidated…

4 weeks ago

Press Release: Sanofis Board of Directors proposes the appointment of Christel Heydemann as an independent director

Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an independent director  Paris, March 5, 2026. The Board of Directors of Sanofi has…

4 weeks ago

Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute

Study is Real-World Evaluation of the Clinical Utility of Sodium Thiosulfate Injection (PEDMARK®) in Reducing the Risk of Ototoxicity in Adolescent…

4 weeks ago

TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Presented positive updated data from the ALLOHA™ Phase 1 heme trial at 67th American Society of Hematology (ASH) Annual Meeting…

4 weeks ago

Kamada to Announce Fiscal Year and Fourth Quarter 2025 Financial Results on March 11, 2026

Company to Host Conference Call at 8:30am ET March 04, 2026 07:00 ET  | Source: Kamada Ltd. REHOVOT, Israel, and…

4 weeks ago

Persevere Therapeutics Launches as a Clinical-Stage Oncology Company with a Novel Phase 1b/2a Agent and Announces First Close of Seed Financing

Chesterbrook, PA, March 03, 2026 (GLOBE NEWSWIRE) -- Persevere Therapeutics, Inc. (“Persevere”), a Delaware-incorporated, clinical-stage oncology biotechnology company, today announced…

4 weeks ago

Inteleos 2026 Leadership Elections Accelerate Vision for Global Healthcare

ROCKVILLE, Md., March 03, 2026 (GLOBE NEWSWIRE) -- Inteleos today announced its 2026 leadership elections that build on more than…

4 weeks ago

Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical…

4 weeks ago

RadNet, Inc. to Present at the Raymond James 47th Annual Institutional Investors Conference on Tuesday, March 3rd, 2026

March 02, 2026 13:16 ET  | Source: RadNet, Inc. LOS ANGELES, March 02, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:…

1 month ago